Mediwhale, an AI-powered health diagnostics company, has raised $12 million in Series A2 funding to drive its global expansion in cardiovascular and metabolic disease management. The investment round was led by Korea Development Bank (KDB), with participation from Woori Venture Partners, IMM Investment, and Mirae Asset Securities. This funding follows Mediwhale’s previous Series A and Pre-A investments, bringing its total funding to $23 million.
Mediwhale’s flagship product, Reti-CVD, uses AI-powered retina scans to predict cardiovascular disease risk. The radiation-free test offers highly accurate results comparable to traditional cardiac CT scans. As of August 2024, Reti-CVD has been used in over 7,200 cases across 57 medical institutions in Korea since gaining private reimbursement approval in June 2023.
The new capital will be used to further develop Mediwhale’s AI algorithms, secure U.S. FDA approval for Reti-CVD, and expand globally. Mediwhale also plans to introduce new products for predicting chronic kidney disease risk.
CEO Kevin Choi emphasized the company’s commitment to advancing AI in healthcare: “With our pioneering technology, we aim to lead the global market in cardiovascular and metabolic disease management.”
